Principal Street Partners LLC Invests $472,000 in Haleon plc (NYSE:HLN)

Principal Street Partners LLC purchased a new stake in Haleon plc (NYSE:HLN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 49,467 shares of the company's stock, valued at approximately $472,000.

A number of other institutional investors also recently modified their holdings of the business. Wolverine Trading LLC purchased a new stake in shares of Haleon during the fourth quarter worth $208,000. Voloridge Investment Management LLC purchased a new stake in Haleon during the 4th quarter worth about $5,499,000. Waverly Advisors LLC bought a new position in Haleon in the 4th quarter worth about $298,000. Vident Advisory LLC boosted its stake in Haleon by 99.3% in the 4th quarter. Vident Advisory LLC now owns 67,066 shares of the company's stock worth $640,000 after purchasing an additional 33,415 shares during the period. Finally, Two Sigma Advisers LP purchased a new position in Haleon during the 4th quarter valued at about $2,391,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HLN. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a report on Friday, May 9th. Barclays reiterated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. HSBC restated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Five equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Haleon presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.25.

Haleon Stock Performance

Haleon stock opened at $10.89 on Tuesday. Haleon plc has a fifty-two week low of $8.25 and a fifty-two week high of $10.95. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market cap of $49.09 billion, a P/E ratio of 32.03, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The firm's fifty day moving average price is $10.23 and its 200-day moving average price is $9.87.

Haleon (NYSE:HLN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. On average, equities research analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a dividend yield of 1.6%. This is a boost from Haleon's previous -- dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon's dividend payout ratio (DPR) is currently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.